Evidence map›Paper›PMID 29426293›Full record

ArticleBMC cancer2018

Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.

Melissa Brackmann, Marina Stasenko, Shitanshu Uppal, Jake Erba, R Kevin Reynolds, Karen McLean

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Frontiers of Ovarian Carcinosarcoma.Current treatment options in oncology · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Melissa BrackmannDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA.
Marina StasenkoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA.
Shitanshu UppalDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA.
Jake ErbaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA.
R Kevin ReynoldsDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA.
Karen McLeanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA. karenmcl@umich.edu.ORCID 0000-0001-7833-1967
University of Michigan · US

Funding

University of Michigan Department of Obstetrics and Gynecology Ansbacher Resident Research Fund 325471
6 · The paper itself

Abstract

backgroundThe optimal first-line chemotherapy for ovarian carcinosarcoma has not yet been determined. We therefore sought to determine the progression-free survival (PFS) and overall survival (OS) for patients with ovarian carcinosarcoma treated at our institution with different first-line chemotherapy regimens.

methodsThis single-institution, retrospective analysis included all patients with ovarian or primary peritoneal carcinosarcoma diagnosed from September 1996 to July 2017. Kaplan Meier analysis with a log-rank Mantel-Cox test was used to compare PFS and OS between treatment groups, and a p-value of < 0.05 was considered statistically significant.

resultsThirty-one patients met inclusion criteria: two patients were stage IC, 5 were stage II, 21 were stage III, and 3 were stage IV. The median PFS and OS for all stages was 9.3 and 19.7 months respectively. Fifteen patients (48%) received carboplatin/paclitaxel as first therapy, 7 (23%) received ifosfamide/paclitaxel, 6 (19%) received a different regimen, and 3 (10%) did not receive chemotherapy. Patients treated with carboplatin/paclitaxel had a statistically significant longer PFS when compared to those receiving ifosfamide/paclitaxel (17.8 vs. 8.0 months, p = 0.025). OS was similar between all comparisons.

conclusionsIn summary, in our cohort of ovarian carcinosarcoma patients, median PFS is longer in patients treated with carboplatin/paclitaxel compared to ifosfamide/paclitaxel. Overall survival was similar for all treatment groups, potentially due to subsequent treatment crossover. Given the rarity and aggressive nature of this tumor, further study into optimal first-line chemotherapy is warranted.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinosarcomaDisease-Free SurvivalFemaleHumansIfosfamideKaplan-Meier EstimateMiddle AgedOvarian NeoplasmsPaclitaxelRetrospective StudiesTreatment OutcomeCarboplatinIfosfamidePaclitaxelCarboplatinChemotherapyIfosfamideMMMTOutcomesOvarian carcinosarcoma

Identifiers

PMID29426293
PMCPMC5810191
OpenAlexW2786222180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.